FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Falchook, G. S. [1 ]
Zhou, X. [2 ]
Rosen, L. S. [3 ]
Venkatakrishnan, K. [2 ]
Kurzrock, R. [1 ]
Mahalingam, D. [4 ]
Goldman, J. [5 ]
Jung, J. [6 ]
Milch, C. [2 ]
Sarantopoulos, J. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Millennium Pharmaceut Inc, Clin Pharmacol, Cambridge, MA USA
[3] Premiere Oncol, Oncol, Santa Monica, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA
[5] UCLA Med Ctr, David Geffen Sch Med, Div Hematol Oncol, Santa Monica, CA USA
[6] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [1] The effect of food on the pharmacokinetics of the investigational Aurora A kinase (AAK) inhibitor, alisertib (MLN8237), in patients (pts) with advanced solid tumors or lymphomas
    Zhou, X.
    Bauer, T. M.
    Goel, S.
    Sarantopoulos, J.
    Zhang, B.
    Kelly, V.
    Mertz, J.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 109 - 109
  • [2] Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
    Falchook G.S.
    Zhou X.
    Venkatakrishnan K.
    Kurzrock R.
    Mahalingam D.
    Goldman J.W.
    Jung J.A.
    Ullmann C.D.
    Milch C.
    Rosen L.S.
    Sarantopoulos J.
    Drugs in R&D, 2016, 16 (1) : 45 - 52
  • [3] The effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors or lymphomas
    Zhou, X.
    Nemunaitis, J.
    Pant, S.
    Bauer, T.
    Lockhart, A.
    Patel, M.
    Zhang, B.
    Kelly, V.
    Ullmann, C. D.
    Bargfrede, M.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 21 - 22
  • [4] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumors
    Dees, E. C.
    Infante, J. R.
    Burris, H. A.
    Astsaturov, I. A.
    Stinchcombe, T.
    Liu, H.
    Galvin, K.
    Venkatakrishnan, K.
    Fingert, H. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] ABSORPTION, METABOLISM, AND EXCRETION OF ALISERTIB (MLN8237), AN AURORA A KINASE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
    Pusalkar, Sandeepraj
    Zhou, Xiaofei
    Li, Yuexian
    Cohen, Lawrence
    Liao, Mingxiang
    Yang, Johnny
    Chong, Saeho
    Venkatakrishnan, Karthik
    Chowdhury, Swapan
    DRUG METABOLISM REVIEWS, 2015, 47 : 195 - 195
  • [6] Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors
    Falchook, Gerald S.
    Venkatakrishnan, Karthik
    Sarantopoulos, John
    Kurzrock, Razelle
    Mita, Alain C.
    Fu, Siqing
    Mita, Monica M.
    Zhou, Xiaofei
    Jung, Jung Ah
    Ullmann, Claudio Dansky
    Milch, Catherine
    Rosen, Lee S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (07) : 563 - 572
  • [7] Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
    Pusalkar, Sandeepraj
    Zhou, Xiaofei
    Li, Yuexian
    Cohen, Lawrence
    Yang, Jun Johnny
    Balani, Suresh K.
    Xia, Cindy
    Shyu, Wen Chyi
    Lu, Chuang
    Venkatakrishnan, Karthik
    Chowdhury, Swapan K.
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (03) : 217 - 229
  • [8] Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors
    Benaim, Ely
    Zhou, Xiaofei
    Liu, Hua
    Leonard, E. Jane
    Freedland, Eric
    Niculescu, Liviu
    BLOOD, 2012, 120 (21)
  • [9] Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies
    Zhou, X.
    Nemunaitis, J.
    Pant, S.
    Bauer, T. M.
    Patel, M.
    Sarantopoulos, J.
    Lockhart, A. C.
    Goodman, D.
    Zhang, B.
    Ullmann, C. Dansky
    Mould, D. R.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S76 - S77
  • [10] Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors
    Xiaofei Zhou
    Sandeepraj Pusalkar
    Swapan K. Chowdhury
    Shawn Searle
    Yuexian Li
    Claudio Dansky Ullmann
    Karthik Venkatakrishnan
    Investigational New Drugs, 2019, 37 : 666 - 673
12345